isoxazoles has been researched along with Alzheimer Disease in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.70) | 18.7374 |
| 1990's | 9 (33.33) | 18.2507 |
| 2000's | 4 (14.81) | 29.6817 |
| 2010's | 8 (29.63) | 24.3611 |
| 2020's | 5 (18.52) | 2.80 |
| Authors | Studies |
|---|---|
| Claeysen, S; Dallemagne, P; Davis, A; Lalut, J; Lecoutey, C; Legay, R; Payan, H; Rochais, C; Sopkova-de Oliveira Santos, J | 1 |
| Gzielo, K; Krawczyk, M; Nikiforuk, A; Popik, P; Potasiewicz, A | 1 |
| Akbarzadeh, T; Edraki, N; Firuzi, O; Hariri, R; Mahdavi, M; Mirfazli, SS; Rastegari, A; Saeedi, M | 1 |
| Akbarzadeh, T; Edraki, N; Felegari, P; Firuzi, O; Hariri, R; Iraji, A; Mahdavi, M; Mirfazli, SS; Rastegari, A; Saeedi, M | 1 |
| Ahmad, B; Ali, M; Ali, T; Anwar, F; Imran, M; Ismail, T; Nadeem, H; Saleem, U | 1 |
| Meng, J; Qian, S; Xu, Y; Yu, M; Zang, D | 1 |
| Ben Jannet, H; Bouajila, J; Bousejra-El Garah, F; Filali, I; Znati, M | 1 |
| Allouche, F; Cacabelos, R; Chabchoub, F; Cherif, O; Chioua, M; López, MG; Marco-Contelles, J; Romero, A; Soriano, E; Yañez, M | 1 |
| Angadi, V; Dissel, S; Donlea, J; English, D; Kirszenblat, L; Klose, M; Koch, Z; Shaw, PJ; Suzuki, Y; van Swinderen, B; Winsky-Sommerer, R | 1 |
| Bouajila, J; Filali, I; Jannet, HB; Romdhane, A; Znati, M | 1 |
| Aravagiri, M; Bies, RR; Coley, K; Feng, Y; Kirshner, M; Marder, S; Miller, D; Pollock, BG; Schneider, L | 1 |
| Al-Abed, Y; Aljabari, B; Bacher, M; Deuster, O; Dodel, R; Egensperger, R; Jessen, F; Neff, F; Noelker, C; Popp, J; Reese, JP | 1 |
| Anyama, NG; Bies, RR; Lieberman, JA; Marder, SR; Pollock, BG; Schneider, LS; Wessels, AM | 1 |
| Choi, SH; Hwang, SH; Jang, CG; Kang, J; Kim, HC; Kim, HJ; Kwon, SH; Lee, BH; Lee, JH; Nah, SY; Shin, EJ; Shin, TJ | 1 |
| Baumann, K; Dyrks, T; Krause, S; Leuchtenberger, S; Mandelkow, E; Narlawar, R; Pickhardt, M; Schmidt, B; Weggen, S | 1 |
| Auchus, AP; Freeman, A; Green, RC | 1 |
| Davis, YB; Jeanblanc, W | 1 |
| Hansen, JJ; Krogsgaard-Larsen, P; Madsen, U; Schousboe, A; Wahl, P | 1 |
| Brioni, JD; Buckley, MJ; Decker, MW; Giardina, WJ; Kang, CH; Kim, DJ; Radek, RJ; Raszkiewicz, JL; Sullivan, JP; Wasicak, JT | 1 |
| Arneric, SP; Bannon, AW; Briggs, CA; Brioni, JD; Decker, MW; Donnelly-Roberts, D; Kyncl, J; Marsh, KC; Radek, RJ; Sullivan, JP | 1 |
| Nordberg, A; Warpman, U | 1 |
| Brown-Proctor, C; Kilbourn, MR; Sherman, PS; Snyder, SE | 1 |
| Katz, IR; Streim, J | 1 |
| Corwin, J; Lang, J; Lenox, R; Newhouse, PA; Piasecki, M; Potter, A | 1 |
| Bruno, G; Chase, TN; Cox, C; Fedio, P; Foster, N; Gillespie, M; Hare, TA; Mohr, E; Tamminga, C | 1 |
1 review(s) available for isoxazoles and Alzheimer Disease
| Article | Year |
|---|---|
Excitatory amino acid research in Alzheimer's disease: enhancement and blockade of receptor functions.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Animals; Humans; Ibotenic Acid; Isoxazoles; Propionates; Receptors, Amino Acid; Receptors, AMPA; Receptors, Glutamate | 1993 |
3 trial(s) available for isoxazoles and Alzheimer Disease
| Article | Year |
|---|---|
Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-Alzheimer's disease trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Area Under Curve; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Isoxazoles; Male; Paliperidone Palmitate; Proportional Hazards Models; Pyrimidines; Risperidone; Time Factors; Treatment Outcome | 2010 |
Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Cognition; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hydrocortisone; Isoxazoles; Learning; Male; Memory; Middle Aged; Nicotinic Agonists; Prolactin; Psychomotor Performance; Pyrrolidines | 1999 |
GABA-agonist therapy for Alzheimer's disease.
Topics: Alzheimer Disease; Clinical Trials as Topic; gamma-Aminobutyric Acid; Humans; Isoxazoles; Middle Aged; Neuropsychological Tests; Oxazoles; Somatostatin | 1986 |
23 other study(ies) available for isoxazoles and Alzheimer Disease
| Article | Year |
|---|---|
Rational design of novel benzisoxazole derivatives with acetylcholinesterase inhibitory and serotoninergic 5-HT
Topics: Acetylcholinesterase; Alzheimer Disease; Binding Sites; Cholinesterase Inhibitors; Donepezil; Drug Design; Humans; Isoxazoles; Models, Molecular; Molecular Docking Simulation; Receptors, Serotonin, 5-HT4 | 2020 |
Positive allosteric modulators of alpha 7 nicotinic acetylcholine receptors enhance procognitive effects of conventional anti-Alzheimer drugs in scopolamine-treated rats.
Topics: Allosteric Regulation; alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Animals; Cholinergic Antagonists; Cholinesterase Inhibitors; Disease Models, Animal; Donepezil; Drug Synergism; Excitatory Amino Acid Antagonists; Galantamine; Isoxazoles; Memantine; Nootropic Agents; Phenylurea Compounds; Rats; Recognition, Psychology; Scopolamine | 2020 |
Design and Synthesis of Novel Arylisoxazole-Chromenone Carboxamides: Investigation of Biological Activities Associated with Alzheimer's Disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Chromones; Dose-Response Relationship, Drug; Drug Design; Electrophorus; Horses; Isoxazoles; Molecular Docking Simulation; Molecular Structure; Neuroprotective Agents; PC12 Cells; Peptide Fragments; Rats; Structure-Activity Relationship | 2020 |
Novel N-benzylpiperidine derivatives of 5-arylisoxazole-3-carboxamides as anti-Alzheimer's agents.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Isoxazoles; Molecular Docking Simulation; Molecular Structure; Neuroprotective Agents; PC12 Cells; Piperidines; Rats; Structure-Activity Relationship | 2021 |
Screening of Synthetic Isoxazolone Derivative Role in Alzheimer's Disease: Computational and Pharmacological Approach.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Drug Evaluation, Preclinical; Elevated Plus Maze Test; Female; Isoxazoles; Male; Mice; Molecular Docking Simulation; Neuroprotective Agents; Open Field Test; Peptide Fragments; Protein Binding; Streptozocin; tau Proteins | 2021 |
Protective effect of ISO‑1 against advanced glycation end product aggravation of PC12 cell injury induced by Aβ1‑40.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Proliferation; Cell Survival; Glycation End Products, Advanced; Intramolecular Oxidoreductases; Isoxazoles; Macrophage Migration-Inhibitory Factors; PC12 Cells; Peptide Fragments; Protective Agents; Rats | 2019 |
Synthesis of new isoxazoline derivatives from harmine and evaluation of their anti-Alzheimer, anti-cancer and anti-inflammatory activities.
Topics: Acetylcholinesterase; Alzheimer Disease; Anti-Inflammatory Agents; Antineoplastic Agents; Arachidonate 5-Lipoxygenase; Cell Proliferation; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Harmine; HCT116 Cells; Humans; Inflammation; Isoxazoles; Lipoxygenase Inhibitors; MCF-7 Cells; Molecular Structure; Structure-Activity Relationship | 2015 |
Isoxazolotacrines as non-toxic and selective butyrylcholinesterase inhibitors for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cell Survival; Cholinesterase Inhibitors; HEK293 Cells; Hep G2 Cells; Humans; Isoxazoles; Molecular Docking Simulation; Protein Binding; Recombinant Proteins; Tacrine | 2014 |
Sleep restores behavioral plasticity to Drosophila mutants.
Topics: Adenylyl Cyclases; Alzheimer Disease; Animals; Animals, Genetically Modified; Behavior, Animal; Disease Models, Animal; Drosophila melanogaster; Drosophila Proteins; Fatty Acid-Binding Proteins; Female; Isoxazoles; Male; Memory, Long-Term; Memory, Short-Term; Mutation; Organophosphorus Compounds; Receptors, GABA; Reserpine; Sleep | 2015 |
Synthesis of New Harmine Isoxazoles and Evaluation of their Potential Anti-Alzheimer, Anti-inflammatory, and Anticancer Activities.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Carbon-13 Magnetic Resonance Spectroscopy; Cholinesterase Inhibitors; Cycloaddition Reaction; Harmine; HCT116 Cells; Humans; Isoxazoles; Lipoxygenase Inhibitors; MCF-7 Cells; Peganum; Proton Magnetic Resonance Spectroscopy; Structure-Activity Relationship; Tamoxifen; Xanthine Oxidase | 2016 |
Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study.
Topics: Adult; Age Factors; Aged; Alzheimer Disease; Antipsychotic Agents; Biological Availability; Body Weight; Female; Humans; Isoxazoles; Male; Metabolic Clearance Rate; Middle Aged; Models, Chemical; Models, Statistical; Paliperidone Palmitate; Pyrimidines; Randomized Controlled Trials as Topic; Risperidone; Sample Size; Sampling Studies; Schizophrenia | 2008 |
The role of macrophage migration inhibitory factor in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; Brain; Brain Chemistry; Cell Survival; Female; Histocytochemistry; Humans; Intramolecular Oxidoreductases; Isoxazoles; Macrophage Migration-Inhibitory Factors; Male; Mice; Mice, Transgenic; Neuroblastoma; Protease Nexins; Receptors, Cell Surface; Statistics, Nonparametric; Tumor Cells, Cultured | 2010 |
Gintonin, a ginseng-derived lysophosphatidic acid receptor ligand, attenuates Alzheimer's disease-related neuropathies: involvement of non-amyloidogenic processing.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; Brain; Calcium; Calcium-Binding Proteins; Cell Survival; Disease Models, Animal; Donepezil; Dose-Response Relationship, Drug; Egtazic Acid; Enzyme Inhibitors; Glycoproteins; Humans; Indans; Isoxazoles; Ligands; Maze Learning; Memory Disorders; Metalloproteases; Mice; Mice, Transgenic; Microfilament Proteins; Mutation; Neuroblastoma; Nootropic Agents; Panax; Peptide Fragments; Phytotherapy; Piperidines; Plant Proteins; Presenilin-1; Propionates; Protein Binding; Receptors, Lysophosphatidic Acid; Signal Transduction; Time Factors; Transfection | 2012 |
Cox-2 inhibitors: still no decisive action.
Topics: Alzheimer Disease; Cardiovascular Diseases; Clinical Trials as Topic; Colorectal Neoplasms; Contraindications; Cyclooxygenase Inhibitors; Drug Industry; France; Government Regulation; Humans; Isoxazoles; Lactones; Pyrazoles; Risk Assessment; Sulfonamides; Sulfones; United States; United States Food and Drug Administration | 2005 |
Curcumin-derived pyrazoles and isoxazoles: Swiss army knives or blunt tools for Alzheimer's disease?
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Cell Proliferation; Cells, Cultured; Chickens; Curcumin; Enzyme Inhibitors; Fluorescence Resonance Energy Transfer; Humans; Inhibitory Concentration 50; Isoxazoles; Magnetic Resonance Spectroscopy; Pyrazoles; Radioligand Assay; tau Proteins | 2008 |
Agitated behavior relieved following treatment of cervical dystonia in dementia.
Topics: Alzheimer Disease; Botulinum Toxins; Chlorpromazine; Dystonia; Female; Humans; Isoxazoles; Middle Aged; Neck Muscles; Phenytoin; Piperidines; Risperidone; Valproic Acid | 1995 |
Risperidone for treating dementia-associated aggression.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Dementia; Dementia, Vascular; Female; Humans; Isoxazoles; Male; Piperidines; Psychotropic Drugs; Risperidone; Treatment Outcome | 1995 |
(S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization.
Topics: Alzheimer Disease; Animals; Anti-Anxiety Agents; Anticonvulsants; Avoidance Learning; Behavior, Animal; Body Temperature; Brain; Cerebrovascular Circulation; Cognition; Electroencephalography; Isoxazoles; Male; Mice; Mice, Inbred Strains; Motor Activity; Nicotine; Nociceptors; Pyrrolidines; Rats; Rats, Wistar; Receptors, Cholinergic; Seizures; Vomiting | 1994 |
Potential treatment of Alzheimer disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like, and cytoprotective properties.
Topics: Alzheimer Disease; Animals; Anti-Anxiety Agents; Avoidance Learning; Cognition; Dose-Response Relationship, Drug; Isoxazoles; Nicotine; Nicotinic Agonists; Pyrrolidines; Rats | 1995 |
Epibatidine and ABT 418 reveal selective losses of alpha 4 beta 2 nicotinic receptors in Alzheimer brains.
Topics: Aged; Aged, 80 and over; Alkaloids; Alzheimer Disease; Animals; Anti-Anxiety Agents; Azocines; Binding, Competitive; Bridged Bicyclo Compounds, Heterocyclic; Cells, Cultured; Humans; Isoxazoles; Kinetics; Mice; Nicotine; Nicotinic Agonists; Pyridines; Pyrrolidines; Quinolizines; Receptors, Nicotinic; Temporal Lobe; Transfection | 1995 |
Synthesis and evaluation of 6-[11C]methoxy-3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-1,2- benzisoxazole as an in vivo radioligand for acetylcholinesterase.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Brain; Carbon Radioisotopes; Female; Isoxazoles; Macaca nemestrina; Mice; Piperidines; Tomography, Emission-Computed | 1999 |
New drugs may help treat psychoses.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Clozapine; Drug Costs; Humans; Isoxazoles; Nursing Homes; Piperidines; Psychotic Disorders; Research; United States | 1995 |
Health news. The sleeper syndrome.
Topics: Alzheimer Disease; Cacao; Humans; Hygiene; Isoxazoles; Margarine; Nicotine; Parkinson Disease; Pyrrolidines; Superoxides | 2001 |